Akums Drugs and Pharmaceuticals IPO Details Today, GMP Price, Date, Review

Akums Drugs and Pharmaceuticals Details Today, GMP Price, Date, Review

Akums Drugs and Pharmaceuticals IPO Details Today : Akums Drugs and Pharmaceuticals IPO is Open on [.] 2024 and Close on [.] 2024. 3C IT Solutions & Telecoms IPO to Raise [.] shares (Approx ₹[.] Cr) via IPO. The Fresh issue of [.] shares (Approx ₹[.] Cr) and The Offer For Sale is [.] shares of ₹[.] (Approx ₹[.] Cr).

Established in 2004, we are a pharmaceutical contract development and manufacturing organization (“CDMO”) offering a comprehensive range of pharmaceutical products and services in India and overseas. As one of the leading CDMOs in India, we own the intellectual property for the manufacturing processes of several of our formulations, and our core business is focused on providing end-to-end product development and manufacturing solutions to our clients.

Some of our other services include formulation research and development (“R&D”), preparation and filing of regulatory dossiers in the Indian and global markets, and other testing services. In addition to our core CDMO business. we are also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (“APIs”) .

We produce an extensive range of dosage forms including tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies, among others. we have manufactured 4,025 commercialised formulations across over 60 dosage forms.

key clients for our CDMO business include Alembic Pharmaceuticals, Alkem Laboratories, Blue Cross Laboratories, Cipla, Dabur India, Dr. Reddy’s Laboratories, Hetero Healthcare, Ipca Laboratories, Mankind Pharma, MedPlus Health Services, Micro Labs, Mylan Pharmaceuticals, Natco Pharma, Sun Pharmaceutical Industries, UCB, and Amishi Consumer Technologies (The Mom’s Co), among others.

Akums Drugs and Pharmaceuticals Details Today, GMP Price, Date, Review

Our international presence extends across 60 countries, and our key clients include Allegens (Vietnam), Ambica International (Philippines), Caferma SAC (Peru), JDS (Myanmar), Master Pharma (Cambodia), Olainfarm (Latvia), Pharma Apex (Myanmar), Planet Pharmaceutical (Tanzania), and Unisel (Kenya), among others.

Object of the Issue

  1.  Repayment/ prepayment of indebtedness of our Company and its Subsidiaries.
  2.  Funding incremental working capital requirements of our Company.
  3.  Pursuing inorganic growth initiatives through acquisitions.
  4.  General corporate purposes.

Our Company Promoter

  1. Sanjeev Jain
  2. Sandeep Jain

Qualitative Factors

  •  Largest India-focused CDMO serving the Indian domestic pharmaceutical industry.
  •  Diverse client base with longstanding CDMO relationships.
  •  Large and rapidly growing R&D capabilities across our product portfolio.
  •  Strategic presence across the pharmaceutical value chain.
  •  Experienced and entrepreneurial management team with a proven track record and marquee healthcare focused PE investor.

Comparison of accounting ratios with Listed Industry Peers

  1. Akums Drugs and Pharmaceuticals
  2. Divi’s Laboratories
  3. Suven Pharma
  4. Gland Pharma
  5. Torrent Pharma
  6. Alkem Laboratories
  7. Eris Lifesciences
  8. JB Chemicals
  9. Mankind Pharma
  10. Innova Captab


Akums Drugs and Pharmaceuticals Company Contact Details

304 Mohan Place
LSC Saraswati Vihar
Delhi -110 034, India
Tel: +91 11 6904 1000
Website: www.akums.in

Akums Drugs and Pharmaceuticals IPO Registrar

Link Intime India Private Limited
C-101, 1stFloor, 247 Park,
Lal Bahadur Shastri Marg, Vikhroli (West)
Mumbai -400 083
Maharashtra, India
Tel:+91 810 811 4949
Investor grievance e-mail:akumsdrugs.ipo@linkintime.co.in
Contact person:Shanti Gopalkrishnan

Leave a Comment